6results about How to "Reduce lesions" patented technology

The present application relates to the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and belongs to the technical field of biological medicine. In order to solve the technical problems that the existing atherosclerosis treatment target is single, cannot target regulate chronic inflammation of blood vessels, and is difficult to suppress disease progression from the root, the present application provides the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and the gene silencing preparation is a recombinant lentivirus vector carrying shRNA targeting GBP4. The present application first finds that GBP4 is a positive regulator of atherosclerosis, and the GBP4 gene silencing preparation can reduce the area of atherosclerotic plaque, delay the occurrence and development of atherosclerosis; increase the thickness of the fibrous cap of the plaque, enhance the stability of the plaque, and reduce the risk of plaque rupture; at the same time, reduce the systemic inflammation level, reduce the inflammatory response of the blood vessel wall, and have important clinical application value and broad market prospect.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

The application relates to the technical field of animal infectious disease prevention and control, and particularly discloses application of tetrandrine in preparation of a medicine for preventing and treating pseudorabies of pigs. The application can significantly inhibit the replication efficiency of PRV on Vero cells and IPAM cells. When the concentration of the inhibitor is higher than 4 muM, the progeny virus titer and the virus gene transcription level of PRV are significantly reduced compared with those of a control group, and the pathological changes caused by cell infection are effectively relieved, which indicates that the tetrandrine can effectively inhibit the proliferation of PRV and has a potential application prospect.

The invention relates to the technical field of medicine application, and discloses mulberry leaf polysaccharide, a preparation method and application of the mulberry leaf polysaccharide in treatment of AFB1-induced mouse liver injury. The mulberry leaf polysaccharide can be independently used, and can also be combined with other traditional Chinese medicine extracts to prepare a pharmaceutical composition together. Experimental results show that the liver injury symptom of the mouse treated by the mulberry leaf polysaccharide is obviously improved, the liver index decline trend is relieved, and the liver lesion degree is obviously relieved. Therefore, the mulberry leaf polysaccharide disclosed by the invention can effectively treat liver injury caused by AFB1 and accompanied oxidative stress, and has a wide application prospect in the research field of mulberry leaf polysaccharide antioxidant preparations. The discovery not only provides powerful support for subsequent research and development of the polysaccharide, but also provides a new thought and direction for further optimization and innovation.

The invention discloses application of magnolol and pharmaceutically acceptable salts thereof in inhibiting bone marrow-derived foam macrophage chronic inflammation after spinal cord injury. The invention provides application of magnolol in preparation of drugs for promoting discharge of macrophage lipid, drugs for promoting spinal cord injury repair, drugs for inhibiting lipid accumulation mediated secondary inflammation after spinal cord injury or neuroprotection drugs. The invention further provides a spinal cord injury repairing drug containing magnolol, a drug or reagent for promoting macrophage lipid excretion and a spinal cord inflammation inhibiting drug. According to the application disclosed by the invention, the magnolol is disclosed for the first time by regulating immune cell lipid excretion-inflammatory factor axis, so that the spinal nerve regeneration is obviously promoted, the nerve function is improved, the inflammatory reaction after lipid overload is relieved, and the spinal cord tissue is protected, and an innovative strategy is provided for spinal cord injury treatment. The magnolol synergistically intervenes the secondary neurodegenerative disease after spinal cord injury by improving lipid overload and immune dual pathways, and a brand new direction is provided for SCI treatment.